Stéphane Manenti

Stéphane Manenti

Auto-generated profile, based on publicly available information

Stéphane Manenti

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1997 in Biochemical Pharmacology
Verified
Journal Article
Closed access
GAGeorgine Agullo
Georgine Agullo
LGLaurence Gamet-Payrastre
Laurence Gamet-Payrastre
SMStéphane Manenti
Stéphane Manenti
CVCécile Viala
Cécile Viala
CRChristian Rémésy
Christian Rémésy
BPBernard Payrastre
Bernard Payrastre

1 March 1999 in General Pharmacology: The Vascular System
Verified
Journal Article
Closed access
LGLaurence Gamet-Payrastre
Laurence Gamet-Payrastre
SMStéphane Manenti
Stéphane Manenti
MGMarie-Pierre Gratacap
Marie-Pierre Gratacap
JTJacques Tulliez
Jacques Tulliez
HCHugues Chap
Hugues Chap
BPBernard Payrastre
Bernard Payrastre

20 September 2011 in Haematologica
Verified
Journal Article
Closed access
FVFrancois Vergez
Francois Vergez
AGA. S. Green
A. S. Green
JTJerome Tamburini-Bonnefoy
Jerome Tamburini-Bonnefoy
JSJ.-E. Sarry
J.-E. Sarry
BGB. Gaillard
B. Gaillard
BVBardet Valerie
Bardet Valerie
Acute myeloid leukemias arise from a rare population of leukemic cells, known as leukemic stem cells, which initiate the disease and contribute to frequent relapses. Although the phenotype of these cells remains unclear in most patients, these cells are enriched within the CD34(+)CD38(low/-) compartment expressing the interleukin-3 alpha chain receptor, CD123. The aim of this study was to determine the prognostic value of the percentage of blasts with the CD34(+)CD38(low/-)CD123(+) phenotype. The percentage of CD34(+)CD38(low/-)CD123(+) cells in the blast population was determined at diagnosis using flow cytometry. One hundred and eleven patients under 65 years of age with de novo acute myeloid leukemia and treated with intensive chemotherapy were retrospectively included in the study. Correlations with complete response, disease-free survival and overall survival were evaluated with univariate and multivariate analyses. A proportion of CD34(+)CD38(low/-)CD123(+) cells greater than 15% at diagnosis and an unfavorable karyotype were significantly correlated with a lack of complete response. By logistic regression analysis, a percentage of CD34(+)CD38(low/-)CD123(+) higher than 15% retained significance with an odds ratio of 0.33 (0.1-0.97; P=0.044). A greater than 1% population of CD34(+)CD38(low/-)CD123(+) cells negatively affected disease-free survival (0.9 versus 4.7 years; P<0.0001) and overall survival (1.25 years versus median not reached; P<0.0001). A greater than 1% population of CD34(+)CD38(low/-)CD123(+) cells retained prognostic significance for both parameters after multivariate analysis. The percentage of CD34(+)CD38(low/-)CD123(+) leukemic cells at diagnosis was significantly correlated with response to treatment and survival. This prognostic marker might be easily adopted in clinical practice to rapidly identify patients at risk of treatment failure.

11 May 2006 in Leukemia
Verified
Journal Article
Open access
PDF file
LYL Ysebaert
L Ysebaert
GCGaëtan Chicanne
Gaëtan Chicanne
CDC Demur
C Demur
FTF De Toni
F De Toni
NPN Prade-Houdellier
N Prade-Houdellier
CRClaire Racaud-Sultan
Claire Racaud-Sultan
Activation of the Wnt/β-catenin pathway has recently been shown to be crucial to the establishment of leukemic stem cells in chronic myeloid leukemia. We sought to determine whether β-catenin was correlated to clonogenic capacity also in the acute myeloid leukemia (AML) setting. Eighty-two patients were retrospectively evaluated for β-catenin expression by Western blot. β-Catenin was expressed (although at various protein levels) in 61% of patients, and was undetectable in the remaining cases. In our cohort, β-catenin expression was correlated with the clonogenic proliferation of AML-colony forming cells (AML-CFC or CFU-L) in methylcellulose in the presence of 5637-conditioned medium, and more strikingly with self-renewing of leukemic cells, as assessed in vitro by a re-plating assay. In survival analyses, β-catenin appeared as a new independent prognostic factor predicting poor event-free survival and shortened overall survival (both with P<0.05). Furthermore, variations in β-catenin protein levels were dependent on post-transcriptional mechanisms involving the Wnt/β-catenin pathway only in leukemic cells. Indeed, β-catenin negative leukemic cells were found to increase β-catenin in response to Wnt3a agonist in contrast to normal counterparts. Altogether, our data pave the way to the evaluation of Wnt pathway inhibition as a new rationale for eradicating the clonogenic pool of AML cells.

9 April 2013 in Leukemia
Verified
Journal Article
Closed access
PDF file
SSS Scotland
S Scotland
ESE Saland
E Saland
NSN Skuli
N Skuli
FTF de Toni
F de Toni
HBH Boutzen
H Boutzen
JSJean-Emmanuel Sarry
Jean-Emmanuel Sarry

18 February 2016 in Blood
Verified
Journal Article
Open access
PDF file
CLClément Larrue
Clément Larrue
ESEstelle Saland
Estelle Saland
HBHéléna Boutzen
Héléna Boutzen
FVFrancois Vergez
Francois Vergez
MDMarion David
Marion David
CRChristian Récher
Christian Récher
Key Points: Bortezomib induces the degradation of FLT3-ITD through an autophagy-dependent mechanism that contributes to cell death. This finding provides a mechanism-based rationale for the study of proteasome inhibitors in FLT3-ITD–mutant acute myeloid leukemia.